(NASDAQ: PRME) Prime Medicine's forecast annual revenue growth rate of 125.1% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.05%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Prime Medicine's revenue in 2025 is $3,846,000.On average, 6 Wall Street analysts forecast PRME's revenue for 2025 to be $1,089,875,263, with the lowest PRME revenue forecast at $337,295,452, and the highest PRME revenue forecast at $2,381,681,396. On average, 3 Wall Street analysts forecast PRME's revenue for 2026 to be $4,051,221,673, with the lowest PRME revenue forecast at $337,295,452, and the highest PRME revenue forecast at $10,503,556,320.
In 2027, PRME is forecast to generate $5,481,018,277 in revenue, with the lowest revenue forecast at $337,295,452 and the highest revenue forecast at $14,792,946,132.